Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-124396
Filing Date
2026-03-25
Accepted
2026-03-25 17:21:23
Documents
73
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K atos-20251231.htm   iXBRL 10-K 2295609
2 EX-4.6 atos-ex4_6.htm EX-4.6 30678
3 EX-10.11 atos-ex10_11.htm EX-10.11 105397
4 EX-21.1 atos-ex21_1.htm EX-21.1 2513
5 EX-23.1 atos-ex23_1.htm EX-23.1 8819
6 EX-31.1 atos-ex31_1.htm EX-31.1 15332
7 EX-31.2 atos-ex31_2.htm EX-31.2 14732
8 EX-32.1 atos-ex32_1.htm EX-32.1 10085
9 EX-32.2 atos-ex32_2.htm EX-32.2 11078
10 GRAPHIC img29443946_0.gif GRAPHIC 10885
11 GRAPHIC gfx29443946_0.jpg GRAPHIC 1098
  Complete submission text file 0001193125-26-124396.txt   8023076

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atos-20251231.xsd EX-101.SCH 1086591
77 EXTRACTED XBRL INSTANCE DOCUMENT atos-20251231_htm.xml XML 1118804
Mailing Address 1448 NW MARKET STREET SUITE 500 SEATTLE WA 98107
Business Address 1448 NW MARKET STREET SUITE 500 SEATTLE WA 98107 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-35610 | Film No.: 26793582
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)